Document is current

Any future updates will be listed below

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)

Crossref DOI link: https://doi.org/10.1186/s12865-021-00473-1

Published Online: 2021-12-25

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark